GlassScriptPhysician profile
Keely Irvine
NPI 1831863331
$1,217.05
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $957 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.26 | 2024-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $169.52 | 2024 | Olumiant, Zepbound, Taltz |
| Galderma Laboratories, L.P. | $167.74 | 2024-2025 | Aklief |
| Pfizer INC. | $113.12 | 2024 | |
| Amgen INC. | $112.99 | 2024-2025 | Otezla |
| Mallinckrodt Hospital Products INC. | $109.48 | 2024-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $74.70 | 2024-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $49.42 | 2024 | |
| Biofrontera INC. | $35.54 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Leo Pharma INC. | $33.33 | 2024 | Adbry |
| Mayne Pharma Commercial LLC | $23.72 | 2024 | |
| Incyte Corporation | $23.55 | 2024 | Opzelura |
| Almirall LLC | $19.30 | 2025 | Klisyri |
| Janssen Biotech, INC. | $17.38 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keely Irvine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.